Tonix Pharmaceuticals Hol... (TNXP)
NASDAQ: TNXP
· Real-Time Price · USD
46.94
-12.64 (-21.22%)
At close: Aug 15, 2025, 10:04 AM
-21.22% (1D)
| Bid | 46.25 |
| Market Cap | 411.49M |
| Revenue (ttm) | 10.04M |
| Net Income (ttm) | -115.1M |
| EPS (ttm) | 2537 |
| PE Ratio (ttm) | 0.02 |
| Forward PE | -7.64 |
| Analyst | Buy |
| Ask | 48.18 |
| Volume | 1,846,121 |
| Avg. Volume (20D) | 1,291,685 |
| Open | 51.92 |
| Previous Close | 59.58 |
| Day's Range | 45.22 - 51.92 |
| 52-Week Range | 6.76 - 130.00 |
| Beta | 1.71 |
About TNXP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TNXP
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TNXP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Tonix Pharmaceuticals has released their quartely earnings
on Aug 11, 2025:
Next Earnings Release
Tonix Pharmaceuticals Holding Corp. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
+32.89%
Tonix Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
1 month ago
+10.43%
Tonix Pharmaceuticals shares are trading higher after the company announced the presentation of new findings on TNX-801 at the Vaccine Congress 2025 in Vienna.
1 month ago · seekingalpha.com
Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A BuyI'm initiating Tonix Pharmaceuticals Holding Corp. with a Buy rating, eyeing a rally on potential FDA approval for flagship drug Tonmya in August. Tonmya targets fibromyalgia, a large, underserved mar...
